Plain-English translation of NCT05780034 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage study testing a new medication called in people with certain types of blood cancer (like chronic lymphocytic leukemia, lymphomas, and related conditions) that have not responded to previous treatments. Researchers want to find the right dose and understand how safe and effective the medication is. The study will enroll about 60 participants across multiple medical centers.
Current treatments don't work well enough for many patients with these blood cancers, especially after they've tried multiple other therapies. This medication works in a new way, and doctors hope it may help patients who have run out of other options or can't tolerate standard treatments.
You likely qualify if…
You likely don't qualify if…
You would take the medication by mouth in 28-day cycles, with your dose potentially adjusted as the study progresses. You'll have regular visits to the clinic for blood tests, physical exams, and monitoring of how you're responding to the treatment and any side effects you experience. The study is 'open-label,' meaning you and your doctors will know you're receiving .
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
United States